MedPath

Tocopherol

Generic Name
Tocopherol
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
-
CAS Number
1406-66-2
Unique Ingredient Identifier
R0ZB2556P8
Background

Tocopherol exists in four different forms designated as α, β, δ, and γ. They present strong antioxidant activities, and it is determined as the major form of vitamin E. Tocopherol, as a group, is composed of soluble phenolic compounds that consist of a chromanol ring and a 16-carbon phytyl chain. The classification of the tocopherol molecules is designated depending on the number and position of the methyl substituent in the chromanol ring. The different types of tocopherol can be presented trimethylated, dimethylated or methylated in the positions 5-, 7- and 8-. When the carbons at position 5- and 7- are not methylated, they can function as electrophilic centers that can trap reactive oxygen and nitrogen species. Tocopherols can be found in the diet as part of vegetable oil such as corn, soybean, sesame, and cottonseed. It is currently under the list of substances generally recognized as safe (GRAS) in the FDA for the use of human consumption.

Indication

Tocopherol can be used as a dietary supplement for patients with a deficit of vitamin E; this is mainly prescribed in the alpha form. Vitamin E deficiency is rare, and it is primarily found in premature babies of very low birth weight, patients with fat malabsorption or patients with abetalipoproteinemia.

Tocopherol, due to its antioxidant properties, is studied for its use in prevention or treatment in different complex diseases such as cancer, atherosclerosis, cardiovascular diseases, and age-related macular degeneration.

Associated Conditions
Vitamin E Deficiency
Associated Therapies
Skin Care
journals.lww.com
·

Parkinson's Disease Trials Could Benefit From Simon Two-stage Design

Simon 2-Stage futility trial design is feasible for early Parkinson's disease treatments, potentially accelerating discovery of new treatments by reducing time, cost, and sample size. The design uses an interim analysis to stop ineffective treatments early, focusing on a 12-month follow-up and a five-point worsening on the UPDRS motor score as primary outcome. However, it has limitations like longer recruitment periods and a higher probability of falsely stopping trials.

Feasibility of Simon 2-Stage Futility Trials in Early Parkinson Disease

Futility trials using the Simon 2-Stage methodology are feasible in Parkinson disease (PD), with a proposed 5-point worsening on the UPDRS motor score as the primary outcome measure and a 12-month follow-up, requiring a sample size of less than 200 participants.
© Copyright 2025. All Rights Reserved by MedPath